ReviewHNO2008
[Immunological principles of allergen-specific immune therapy].
Review in HNO, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases.Allergo journal international · 2018Review
- Effects of local nasal immunotherapy in allergic airway inflammation: Using urea denatured Dermatophagoides pteronyssinus.Human vaccines & immunotherapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immunological mechanisms of healthy and allergic immune responses, as well as allergen-specific immune therapy (ASIT) are determined by the activation of defined subpopulations of specific T-cells and the resulting cytokine pattern. Suppression of a Th2 cytokine pattern by regulatory T-cells (Treg) with IL-10 and/or TGF-beta is decisive for the success of an ASIT. A prerequisite for achieving immunologic tolerance is that sufficiently high amounts of the individual allergen components are present in the allergen extract used. This is true for all forms of application of allergens. Chemically or genetically modified allergens, which will not be recognized by the existing IgE antibodies, can be utilized to attain the high doses required.
Indexed as
Identifiers
18648758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.